Tag: medications

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Pudu Robotics Unveils PuduFM 1.0 and PuduAgent: Defining the Next Era of Humanoid and Embodied AI Systems

Pudu Robotics launches PuduFM 1.0 & PuduAgent, enabling "One Brain, Multiple Embodiments" for scalable service robots across industries.

Tennessee American Water Proudly Recognizes American Water Charitable Foundation 2026 Water and Environment Grantees

Recipients include three nonprofit organizations CHATTANOOGA, Tenn., June 5, 2026 /PRNewswire/ -- The American Water Charitable Foundation, a philanthropic non-profit organization established by American Water (NYSE:...

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

Allergy & Asthma Network Statement on Centers for Medicare & Medicaid Services Work Requirements Interim Final Rule

FAIRFAX, Va., June 4, 2026 /PRNewswire/ -- Allergy & Asthma Network CEO Lynda Mitchell issued the following statement in response to the Centers for Medicare & Medicaid Services...

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsMedications

Looney Tunes™ Land Now Open at Six Flags Magic Mountain

A New Era Begins: Cal Poly Unveils the John Madden Football Center

Crypto News Today: AlphaPepe Presale Hits 9300 Holders While Bitcoin Price Prediction Targets $50,000